Home Analyst Ratings HC Wainwright & Co. reiterates Xenetic Biosciences rating to Buy and...

HC Wainwright & Co. reiterates Xenetic Biosciences [XBIO] rating to Buy and sets new price target at $$2.50

HC Wainwright & Co. maintained its Xenetic Biosciences [XBIO] rating to the equivalent of Buy but changed the price target to $5.0 from $2, in a research note dated 2021-01-11. That figure represents around a 106.61% premium from where the company’s shares closed on Friday.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is Xenetic Biosciences Inc. [NASDAQ:XBIO] a Good Buy Right Now?

It should be noted that XBIO technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 40% Buy in the past month. Data from Xenetic Biosciences Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 1.53 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 4.48 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 2.34 million shares.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


XBIO Price Performance

On Wall Street, Xenetic Biosciences Inc. [NASDAQ:XBIO] finished Friday’s session up 5.22% at $2.42. The stock went up to $2.43 at the same session while its lowest single day price was $2.24. In the last five days, it saw a rise of about 18.63%, Xenetic Biosciences Inc. shares gained by almost 18.63% since the beginning of the year. However, the share price has dropped to as low as -58.63% below its one year high. On 01/06/21, the company shares recorded $2.84, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $2.00. The company’s shares have inclined by 50.31% in the past year. The 50-day SMA achieved is $1.43 while the 200-day SMA is $1.10. Volume dropped to 0.52 million from 0.74 million in the previous session.

XBIO Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is perceived around 2.30 level, and in case of violation of this particular level, it will cause more drop to 2.17 level. On the upper level, 2.55 is still the key resistance. The stock may increase to the subsequent resistance at 2.49. The Relative Strength Index (RSI) pinned on the 14-day chart is 64.47, implying a neutral technical stance while the MACD stands at 0.28, meaning price will decrease in the next trading period. Percent R indicator moved to 36.52%, implying low price movement. Stochastic %K at 60.00% suggest selling the stock.

What is the short interest in Xenetic Biosciences Inc.?

Short interest in the Xenetic Biosciences Inc. stock has surged, increasing by 50130.0 shares to total 0.53 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.58 million, data from Yahoo Finance shows. The decrease of -9.49% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 6.58% of the overall float for the stock.

Xenetic Biosciences Inc.’s Biggest Shareholders: Who Owns Xenetic Biosciences Inc. [XBIO]?

Filings by Renaissance Technologies LLC showed that the firm now holds a total of 59,209 shares or roughly 0.94% of the outstanding XBIO shares. This means their shares have reduced by -113,988 from the 59,209 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Royal Bank of Canada updated stake is worth $30,770. The Morgan Stanley & Co. LLC’s holdings currently number 261 shares at $631.62. According to the firm’s last 13F report, Crewe Advisors, LLC shares in the company at filing stood at 115 shares, roughly $131.

XBIO Earnings Forecast For The Current Quarter

Xenetic Biosciences Inc. [XBIO] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $130k and an earnings per share of -$0.23 for Dec 2020. The estimates represent upside of 117.10% and 59.30% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

XBIO Earnings Estimates For The Current Year

For the financial year, Xenetic Biosciences Inc. [NASDAQ:XBIO] is expected to bring in revenue of $410k. The returns are nearly $0.39 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.67, higher than that of FY19 by $4.66. Estimates put this year’s earnings growth at 73.60%, 59.30% for the next. As for sales, forecasts are for an increase of 2,311.80% in the current fiscal year and a further 117.10% over the following year.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Sino-Global Shipping (SINO) Is Rising Today: Thanks To A Step Forward In Digital Currency

The provider of shipping and freight logistics integrated solutions Sino-Global Shipping America Ltd. (NASDAQ: SINO) has been experiencing an 11.48% rise in its stock...

Why Genesis Healthcare (GEN) Stock Leapt 14% After-Hours? Here Is An Explanation

Shares of medical care facilities provider Genesis Healthcare, Inc. (NYSE: GEN) rose by 14.07% in after-hours trading on Tuesday following indirectly related news of...

Why Maravai LifeSciences (MRVI) Shares Are Up 20% After-Hour

The stock of global provider of life science reagents and services Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI) surged by 19.94% in trading after...

Iridex Corporation (IRIX) Shares Rose 26.27% After-Hour, Thanks To A Strategic Alliance

Iridex Corporation (NASDAQ: IRIX) saw its shares’ price climbing 26.27% in after-hours trading on Tuesday following news of a strategic collaboration with a Japanese...

Inpixon (INPX) Building its Reputation in the market

Inpixon recently got a huge amount of recognition from various firms. INPX company was commended by Gartner and by IoT Sensor company. These recognitions resulted in an overall good impression of the company. This news gave a huge boost to the company and as a result, the company will be looking forward to attracting more investors.

How Come Ovid Therapeutics Is On The Rise Today?

Price of the biopharmaceutical company Ovid Therapeutics Inc. (NASDAQ: OVID) is on an uptick in early trades today. The stock was at a rise...

Moonpay Integrates NEM (XEM) into its global payment solution

NEM is part of the biggest exchange trading competition. NEM (XEM) has established itself as a renowned crypto asset in the market over the years....

Why The KemPharm (KMPH) Stock Has Been Rising More Than 50% In Early Trades?

The specialty pharmaceutical company KemPharm, Inc. (NASDAQ: KMPH) has been seeing its shares skyrocketing in early trades today. As of 10:46 a.m. EST, the...

Related News

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

Raymond James upgrades Atlantic Capital [ACBI] to Outperform

Raymond James took its Atlantic Capital rating to the equivalent of Outperform from Market Perform, in a research note dated 2021-01-25. Other analysts...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.